Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | CTRC | Q99895 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29619533 | 0.91 | GABRA1 (0.41) | GABRA1GABRB2TAAR1HTR1ACTRC | |
| SCHEMBL166573 | 0.91 | GABRA1 (0.41) | GABRA1GABRB2TAAR1HTR1ACTRC | |
| Ammonia Solution, Strong SCHEMBL27539208 | 0.88 | GABRA1 (0.39) | GABRA1GABRB2TAAR1HTR1ACTRC | |
| Ethylene SCHEMBL27502363 | 0.85 | GABRA1 (0.38) | GABRA1GABRB2TAAR1HTR1ACTRC | |
| SCHEMBL10656642 | 0.81 | CYP1A2 (0.37) | GABRA1GABRB2CTRC | |
| SCHEMBL27512807 | 0.81 | TP53 (0.48) | CTRC | |
| SCHEMBL7643316 | 0.80 | GABRA1 (0.35) | GABRA1GABRB2TAAR1HTR1ACTRC | |
| SCHEMBL188099 | 0.78 | GABRA1 (0.33) | GABRA1GABRB2CTRC | |
| SCHEMBL4077011 | 0.78 | PRKCI (0.39) | GABRA1GABRB2CTRC | |
| SCHEMBL1006285 | 0.78 | GABRA1 (0.33) | GABRA1GABRB2CTRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040054173-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040054173-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | IL2, IL1B, IL1A | GABRA1 1869/4885GABRB2 1185/4885TAAR1 827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.